Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.1 SEK | +1.69% | +3.61% | -42.12% |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 155M 14.27M | Sales 2025 * | 238M 21.98M | Capitalization | 1.97B 182M |
---|---|---|---|---|---|
Net income 2024 * | 37M 3.41M | Net income 2025 * | 37M 3.41M | EV / Sales 2024 * | 12 x |
Net cash position 2024 * | 120M 11.05M | Net cash position 2025 * | 93M 8.58M | EV / Sales 2025 * | 7.88 x |
P/E ratio 2024 * |
52.4
x | P/E ratio 2025 * |
22.9
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
1 day | +1.69% | ||
1 week | +3.61% | ||
Current month | +8.08% | ||
1 month | -5.05% | ||
3 months | -35.96% | ||
6 months | -36.30% | ||
Current year | -42.12% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 30.1 | +1.69% | 51,846 |
24-05-08 | 29.6 | -0.34% | 17,178 |
24-05-07 | 29.7 | -2.62% | 178,820 |
24-05-06 | 30.5 | +4.99% | 225,219 |
24-05-03 | 29.05 | +1.93% | 30,962 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.12% | 182M | |
-1.29% | 12.64B | |
-0.47% | 8.46B | |
+22.61% | 5.27B | |
-2.03% | 4.49B | |
-53.56% | 3.11B | |
+19.30% | 2.87B | |
+33.07% | 2.31B | |
-8.42% | 2.23B | |
-3.55% | 1.89B |
- Stock Market
- Equities
- GENO Stock